PMID

Data

Article Title

Organization

GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.

Shanghai University

Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.

Daiichi Sankyo

Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).

Glaxosmithkline

Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.

Daiichi Sankyo

Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes.

University Of Southern Denmark

Discovery of novel orally bioavailable GPR40 agonists.

Shanghai Hengrui Pharmaceutical

Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.

TBA

Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties.

University Of Southern Denmark

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent.

Takeda Pharmaceutical

Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.

Takeda Pharmaceutical

Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.

Takeda Pharmaceutical

AMG 837: a potent, orally bioavailable GPR40 agonist.

Amgen

Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.

Merck Research Laboratories